Get the Stockscreener App
15.60
0.39%
0.06
After Hours:
15.60
Rapport Therapeutics Inc stock is traded at $15.60, with a volume of 145.38K.
It is up +0.39% in the last 24 hours and up +6.85% over the past month.
Rapport Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovery and development of transformational small-molecule medicines for patients suffering from central nervous system disorders. Its foundational science has elucidated the complexities of neuronal receptor biology and enables the company to map and target certain neuronal receptor complexes. Neuronal receptors are complex assemblies of proteins, comprising receptor principal subunits and their receptor-associated proteins (RAPs), the latter of which play crucial roles in regulating receptor expression and function.
See More
Previous Close:
$15.54
Open:
$15.7
24h Volume:
145.38K
Relative Volume:
0.82
Market Cap:
$569.37M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
+6.78%
1M Performance:
+6.85%
6M Performance:
-1.08%
1Y Performance:
-23.38%
1-Day Range:
$15.42
$16.13
1-Week Range:
$13.62
$16.13
52-Week Range:
$7.13
$29.74
Rapport Therapeutics Inc Stock (RAPP) Company Profile
Name
Rapport Therapeutics Inc
Sector
Industry
Phone
857-321-8020
Address
99 HIGH STREET, BOSTON
Compare RAPP with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RAPP
Rapport Therapeutics Inc
|
15.60 | 567.18M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.92 | 99.42B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.55 | 58.99B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
432.52 | 56.35B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
646.60 | 39.02B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
307.51 | 34.25B | 3.81B | -644.79M | -669.77M | -6.24 |
Rapport Therapeutics Inc Stock (RAPP) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-06-25 | Initiated | H.C. Wainwright | Buy |
| Apr-08-25 | Initiated | Citizens JMP | Mkt Outperform |
| Jul-02-24 | Initiated | Jefferies | Buy |
| Jul-02-24 | Initiated | Stifel | Buy |
| Jul-02-24 | Initiated | TD Cowen | Buy |
Rapport Therapeutics Inc Stock (RAPP) Latest News
Rapport Therapeutics Inc. stock prediction for this weekJuly 2025 Levels & Weekly High Momentum Picks - Newser
Can Rapport Therapeutics Inc. hit a new high this monthMarket Rally & Entry Point Confirmation Alerts - Newser
How to manage a losing position in Rapport Therapeutics Inc. [Profit Target]Risk Controlled Swing Trade Alerts - Newser
How hedge fund analytics apply to Rapport Therapeutics Inc. stockJuly 2025 Fed Impact & Weekly High Return Opportunities - Newser
Will Rapport Therapeutics Inc. rebound enough to break evenFree Reliable Chart-Based Trade Entries - Newser
Published on: 2025-08-12 21:34:00 - Newser
Chart based exit strategy for Rapport Therapeutics Inc.Momentum Detection with Entry Optimization - Newser
How to manage a losing position in Rapport Therapeutics Inc.Strategy Builder for Growth Focused Traders - Newser
Published on: 2025-08-12 06:02:16 - Newser
Why Rapport Therapeutics Inc. stock attracts strong analyst attentionSecure Asset Flow and Trend Pattern Analysis - Newser
What momentum shifts mean for Rapport Therapeutics Inc.Reversal Signal Prediction Based on Volume - Newser
Market reaction to Rapport Therapeutics Inc.’s recent newsTrade Safety Matrix for Conservative Traders - Newser
What Fibonacci levels say about Rapport Therapeutics Inc. reboundFree Multi-Bagger Potential Stock Forecast Tools - Newser
Rapport Therapeutics Inc.’s volatility index tracking explainedMarket Downturn Defense Strategy Analysis - Newser
Candlestick signals on Rapport Therapeutics Inc. stock todayReal Time Trade Execution Alert Plan - Newser
Chart overlay techniques for tracking Rapport Therapeutics Inc.Short-Term Growth Watch with Signal Prediction - Newser
Comparing Rapport Therapeutics Inc. in custom built stock radarsFree Risk-Adjusted Picks With Exit Strategy - Newser
What is HC Wainwright’s Estimate for RAPP Q2 Earnings? - Defense World
Rapport Therapeutics (NASDAQ:RAPP) Coverage Initiated at HC Wainwright - Defense World
Rapport Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Rapport Therapeutics' Q2 2025 Update: RAP-219's Precision Neuroscience Potential and September 2025 Catalyst - AInvest
Rapport (RAPP) Q2 Net Loss Widens 47% - AOL.com
Rapport Therapeutics reports Q2 EPS (75c), consensus (79c) - TipRanks
Rapport Therapeutics sees cash runway through end of 2026 - TipRanks
Rapport Therapeutics Reports Q2 2025 Financials and Business Update. - AInvest
Rapport Therapeutics Reports Second Quarter 2025 Financials and Provides Business Update - GlobeNewswire
Press Release: Rapport Therapeutics Reports Second Quarter 2025 Financials and Provides Business Update - 富途牛牛
Rapport Therapeutics (RAPP) Expected to Announce Earnings on Thursday - Defense World
This Palvella Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - Benzinga
HC Wainwright Initiates Rapport Therapeutics at Buy With $31 Price Target - MarketScreener
Is Rapport Therapeutics Inc. Stock a Smart Buy in 2025 Investment Analysis InsideFree Community Entry Consensus Trade Ideas - Newser
Bank of New York Mellon Corp Acquires 15,514 Shares of Rapport Therapeutics, Inc. (NASDAQ:RAPP) - Defense World
Applying chart zones and confluence areas to Rapport Therapeutics Inc.Free Trade Setups With Clear Risk Limits - Newser
Rapport Therapeutics Inc expected to post a loss of 83 cents a shareEarnings Preview - TradingView
AI Indicators Detect Buy Opportunity in Rapport Therapeutics Inc.Community Verified Stock Suggestions Drive Volume - metal.it
Is Rapport Therapeutics Inc. a good long term investmentFree Advanced Stock Screener Access - Jammu Links News
What institutional investors are buying Rapport Therapeutics Inc. stockUnlock expert insights for smarter investing - Jammu Links News
Is Rapport Therapeutics Inc. a growth stock or a value stockConsistently superior profits - Jammu Links News
Does Rapport Therapeutics Inc. stock perform well during market downturnsUnmatched market performance - Jammu Links News
How does Rapport Therapeutics Inc. generate profit in a changing economyAchieve rapid portfolio growth with expert help - Jammu Links News
Rapport Therapeutics Inc Stock (RAPP) Financials Data
There is no financial data for Rapport Therapeutics Inc (RAPP). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
Rapport Therapeutics Inc Stock (RAPP) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Bredt David | Chief Scientific Officer |
Jun 16 '25 |
Sale |
11.00 |
8,500 |
93,522 |
443,642 |
1.67%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):